Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is far from a yawn. when we go north, we go north fast.
A person can argue statistics till we all go blue but a .05% increase month over month is substantial growth.
Well Merck still paid (paying) BMY a lot of money for patent infringements for Opdivo. BMY is the better choice for ADXS as BMY is making BANK on Opdivo and also getting a % of every single Keytruda sale. When considering pd1, Merck is in 2nd place, big time.
The real money will be made by those that invest NOW.
Taking a long term position now is a smart play when attributing potential reward vs potential risk
The Big Shorts are Worried... WOW!
Which websites? Site your references.
Once again, passion from users will not let it fade away. How many BP has passion behind their product? I, personally, am loading up at these levels.
How many passionate users does it take to keep a company alive? If you ask me, at this time, it depends on the marketing to get the product out to the public. Another intriguing question is how many users of any pharmaceutical product approved by the FDA are the end users passionate about?...(fraction of a percentage) From what I have witnessed, I see lots of passion when it comes to Afrezza users. Passionate consumers = DEMAND. Its just a matter of time...
Volume also increased, which that ratio also needs to be included
At some level he almost needs to stop buying shares regarding the normal aspect of things......unless.....you have privileged info (as any ceo would have) and continue to purchase based on where the company is headed.
Passion from the user will change the direction. Any one entity cannot mimic human emotion even when including stats (a joke in this aspect). Stick to your charts and stats though...it should work out, right?
Yet I still buy and feel like I am stealing shares at these levels.
The market is too large (growing worldwide) and the demand/need of the product is too great to let it fade away to nothingness. Lastly, did anyone else pay attention to possible "advertising" being produced in L.A.?
Is it just me or do others see the new website as a "brochure" for a company that is for sale? Anyone that reads my posts know that I don't speculate (much at all) but I cant help but see it as just. The website is literally the best I have seen so far in the industry and it makes me wonder....? Awesome site though, very impressive, and worth the cost to create, imo.
Currently this stock is a battle of the wits, hypi owes you no response, imo. STICK TO YOUR CHARTS, they tell all...right?
Not necessarily. New CEO = new direction. I think their Bio's speak for themselves:
Michael Castagna-
"Entrepreneurial executive with more than 20 years of experience in marketing, sales, medical affairs and strategic development in Fortune 500 companies as well as privately held biotech start-ups. Proven pre-launch and launch experience on over 15 brands in seven distinct disease states with global sales ranging from $250M to over $2Billion. Disciplined, results-driven leader with a personal commitment to developing people and working cross-functionally to achieve core objectives in highly complex and competitive disease states. Specialty disease state expertise: Oncology, Nephrology, GI, Psoriasis, HIV, Hepatitis B & C, Endocrinology, Rheumatoid Arthritis and Infertility."
"Specialties: Strategy, Marketing, Pricing, Managed Care, Clinical Knowledge, Leadership, Generic Industry, Biosimilars, Turn Around and Launch Experience"
Compared to:
Mathew Pfeffer-
"Seasoned financial executive with over 30 years experience, including three public company CFO positions, public company board positions and in-depth knowledge of financing strategies for public companies. Active CPA accreditation and over $1 billion raised to date through well-established Wall Street network."
"Strengths: Strategic planning, mergers and reorganizations (including spin-outs), team building, communications, technical accounting, creative financing"
MannKind Engages Locust Walk to Explore Strategic Options for MannKind's Non-insulin Technosphere-based Pipeline Candidates
Monday 06/05/2017 09:00 AM ET - GlobeNewsWire via Dow Jones News
MannKind Engages Locust Walk to Explore Strategic Options for MannKind's Non-insulin Technosphere-based Pipeline Candidates VALENCIA, Calif., June 05, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) (TASE:MNKD), focused on the discovery, development and commercialization of therapeutic products, announces its decision to explore strategic and financial alternatives for MannKind's novel Technosphere-based pipeline candidates. This Technosphere platform is characterized by an ultra-rapid onset of action, simple and needle-free administration, avoidance of hepatic metabolism, and improved bioavailability. Continuing MannKind's strong desire to help patients, Locust Walk will seek strategic partners and investors to non-dilutively advance the development of Technosphere-based therapies which demonstrate benefit across a variety of treatment areas, including but not limited to hypertension, anaphylactic shock, nausea, respiratory disease and pain.
"Hopefully MNKD is in a silent period currently will all the deal making going on...wink, wink."
My last prediction but you wont acknowledge that.
Thats too bad but indicative of your opinions portrayed on this stock. Enjoy the ride up.
It would be a lot cooler if you gave me at least some credit for my other prediction.
Good looking booth, thanks for posting.
The marketing storm is upon us...soon, little one, soon. 6 months this will be a $10 stock imo.
I am a buyer at these prices Castagna sent a message his 2nd day as CEO with the Biomm deal.
You really should be celebrating 1 down day of 4.32%....Now that is impressive!
You forgot number... (Which number are we on again?) we have a new ceo, mnkd is backed into a corner, and huge gains are to be made with adequate marketing, partnerships, and product education.
No I pick my stocks at random. Also, .98 is my favorite number so i thought it would be good to build my position there.
Here was my last call... Biomm announement was being PR'd as I was writing this:
"Hopefully MNKD is in a silent period currently will all the deal making going on...wink, wink."
So I got a little cocky-
Shorts are giving eachother high-fives because the stock is down 3%, lol. I guess they need to celebrate something after whats happened in the past month.
I spoke with IR earlier regarding if the collab with BMY would start off in PH3. She made it seem that was their intention but as of now they are just not sure until all data is submitted to the FDA and a response is given. I was also told the patient population in the PH(?) study will be large. Also, PETX approval and EMA submission still on par for 2nd half 2017. She was very kind over the phone and said she was extremely busy (couple of times) but said to call anytime.
...In the U.S.
If 1% of the diabetic population starts using afrezza then that would equate to 140,000 new scripts not to mention refills.
Probably not.
A little bit of respect should be given- refer to post #23717 and the timing of the announcement of the BIOMM deal.
Prepared for a gap up and a close of $2.20 tomorrow? Original recipe or extra crispy? Shorts will fry tomorrow, trend.
Look to Advaxis and Aduro for an example. With one of them, management buys stock every month the other management sells every chance they are awarded shares. Both use similar tech and both are way down. It means something and it means nothing if management is not buying. Hopefully MNKD is in a silent period currently will all the deal making going on...wink, wink. All in my opinion.
****** The problem is Marketing, Sales, and Product Education.
The new ceo will take care of marketing and sales.
One drop will help with education.
All IMO
Volume and a very bullish chart mixed with today's news highly suggest the contrary.
You hit the nail on the head iggy. If we were 5% up everyone would be searching for a conclusion to why DO is so awesome given this out of the blue collaboration.
Glad I am not the only one. Thanks for replying.
What is ADXS-DUAL? I don't remember ever hearing anything about DUAL nor what it stands for. Also, does anyone know if this collab/trial starts off in PH 3? I called IR and left a message asking, no reply.